Global Chemotherapy-Induced Anemia Market - 2023-2030
The Global Chemotherapy-Induced Anemia Market size reached USD 2,240 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,893.5 million by 2030. The chemotherapy-induced anemia market is expected to exhibit a cagr of 7.2% during the forecast period (2023-2030).
Anemia is a condition in which the body's status of red blood cells goes below normal. When the body does not contain adequate RBCs, the body parts do not acquire sufficient oxygen. As a consequence, they cannot perform in the manner they require to and induce issues. Individuals conceive anemia if their body does not produce adequate RBCs or eliminates them. Thus, individuals can even induce anemia if they lose too much blood from their bloodstream. Anemia is a typical side consequence of cancer and cancer therapy, specifically true for individuals accepting chemotherapy.
Market Dynamics
The Growing Cases Of Cancer Are Driving The Global Chemotherapy-Induced Anemia Market In The Forecast Period.
The growing cases of cancer are driving the global chemotherapy-induced anemia market during the forecast period. For instance, according to a research study published in 2022 worldwide, an assessed 19.3 million cases and over 10 million demises were because of cancer as registered in GLOBOCAN 2020. Among these entire patients, the incidence of typically detected cancers globally were female prostate cancers (1.41 million, 7.3%), lung (2.21 million, 11.4%), and breast (2.26 million cases, 11.7%).
The Geriatric Population Is Providing The Global Chemotherapy-Induced Anemia Market With Prospective Growth Opportunities.
Cancer can grow at any age, despite as individuals get older, a majority of kinds of cancer become more typical. This is because the body's cells can get harmed over the period. This deterioration can then produce up as individual ages, and can frequently yield cancer. Thus, the growing geriatric population presents the global market with prospective growth opportunities in the upcoming years. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.
COVID-19 Impact Analysis
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
Russia-Ukraine War Impact Analysis
As the warfare in Ukraine released disorder and uprooted millions of individuals, numerous Ukrainians had to escape to the western region of the nation and became refugees in Europe and outside. Among them were individuals with cancer, who encountered a fierce one-two force of extreme sickness and exile. And while cancer hospitals in Ukraine are being deserted or even attacked, Ukrainian patients across the boundary, struck by sanctions and inflation, even encounter an indefinite future for their care.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession as the high inflation in developed countries worldwide has transpired in a general cost surge over the past two years. The cumulatively deteriorating general purchasing control is anticipated to affect growing economies particularly and is considered helpful in numerous ways.
Segment Analysis
The global chemotherapy-induced anemia market is segmented based on disease type, treatment type, drug type, end-user, and region.
The Erythropoiesis-Stimulating Agents (ESAs) Treatment Type Segment Is Estimated To Hold A 34.1% Share Of The Global Market By 2030.
The erythropoiesis-stimulating agents (ESAs) treatment type segment is estimated to hold about 34% of the total chemotherapy-induced anemia market by 2030, owing to the increasing clinical research activities. For instance, in May 2023, FibroGen, Inc., a top biopharmaceutical enterprise committed to finding, creating, and selling a product line of first-in-class therapeutics, and its associate, FibroGen (China) Medical Technology Development Co., Ltd. informed favorable topline information from corporation's Phase 3 clinical trial of roxadustat for the treatment of anemia in people taking coexisting chemotherapy drug for non-myeloid malignancies in China.
Geographical Analysis
Europe is Estimated To Hold The Second-Largest Share Of The Global Chemotherapy-Induced Anemia Market During The Forecast Period.
Owing to the growing number of cancer deaṭhs and measures to battle against cancer, Europe is estimated to hold about 26.6% of the global chemotherapy-induced anemia market by 2030. For instance, according to the 2022 edition of Health at a Glance, cancer is the second largest basis for death in the European Union following cardiovascular conditions. Over 30‑50% of cancer individuals' deaths are avertable, and mortality can also be lowered via premature identification and the essential better punctual, and efficacious cures. Europe’s Beating Cancer Plan aims to lower the burden of cancer and handle cancer-related inequalities among and in the governments, with struggles to aid, harmonize and satisfy the activities of Member States.
Competitive Landscape
The major global players in the market include Dr. Reddy’s Laboratories Ltd, Pfizer Inc, Panacea Biotec Limited, SBI PHARMACEUTICALS CO., LTD, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, Therapure Biopharma Inc., PharmaEssentia Corp., PhytoHealth Corp, and UBI Pharma Inc among others.
Why Purchase the Report?
• To visualize the global chemotherapy-induced anemia market segmentation based on disease type, treatment type, drug type, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chemotherapy-induced anemia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global chemotherapy-induced anemia market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Disease Type
- 3.2. Snippet by Treatment Type
- 3.3. Snippet by Drug Type
- 3.4. Snippet by End User
- 3.5. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Research Activities
- 4.1.1.2. Growing Cancer Prevalence
- 4.1.2. Restraints
- 4.1.2.1. Stringent Regulatory Authorities
- 4.1.3. Opportunity
- 4.1.4. Government Initiatives
- 4.1.5. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter’s 5 Forces Analysis
- 5.2. Regulatory Analysis
- 5.3. Pricing Analysis
- 5.4. Patent Analysis
- 5.5. PEST Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers’ Strategic Initiatives
- 6.6. Conclusion
- 7. Russia-Ukraine War Analysis
- 8. Global Recession Analysis
- 9. By Disease Type
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 9.1.2. Market Attractiveness Index, By Disease Type
- 9.2. Mild Anemia
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Moderate Anemia
- 9.4. Severe Anemia
- 10. By Treatment Type
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.1.2. Market Attractiveness Index, By Treatment Type
- 10.2. RBC Transfusions
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Erythropoiesis-stimulating agents (ESAs)
- 10.4. Iron Supplementation
- 11. By Drug Type
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 11.1.2. Market Attractiveness Index, By Drug Type
- 11.2. Epogen Injection
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Procrit Injection
- 11.4. Androxy Oral
- 11.5. Aranesp injection
- 11.6. Epoetin Alfa Injection
- 11.7. Others
- 12. By End User
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.1.2. Market Attractiveness Index, By End User
- 12.2. Hospitals
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 12.3. Specialty Clinics
- 12.4. Ambulatory Surgical Centers
- 12.5. Cancer Research Centers
- 12.6. Cancer Rehabilitation Centers
- 13. By Region
- 13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
- 13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.2.7.1. The U.S.
- 13.2.7.2. Canada
- 13.2.7.3. Mexico
- 13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.3.7.1. Germany
- 13.3.7.2. The U.K.
- 13.3.7.3. France
- 13.3.7.4. Italy
- 13.3.7.5. Spain
- 13.3.7.6. Rest of Europe
- 13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.4.7.1. Brazil
- 13.4.7.2. Argentina
- 13.4.7.3. Rest of South America
- 13.5. Asia-Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 13.5.7.1. China
- 13.5.7.2. India
- 13.5.7.3. Japan
- 13.5.7.4. Australia
- 13.5.7.5. Rest of Asia-Pacific
- 13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 14. Competitive Landscape
- 14.1. Competitive Scenario
- 14.2. Market Share Analysis
- 14.3. Mergers and Acquisitions Analysis
- 15. Company Profiles
- 15.1. Dr. Reddy’s Laboratories Ltd.
- 15.1.1. Company Overview
- 15.1.2. Disease Type Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
- 15.2. Pfizer Inc
- 15.3. Panacea Biotec Limited
- 15.4. SBI PHARMACEUTICALS CO., LTD
- 15.5. Tolero Pharmaceuticals, Inc.
- 15.6. Vifor Pharma AG
- 15.7. Therapure Biopharma Inc.
- 15.8. PharmaEssentia Corp.
- 15.9. PhytoHealth Corp
- 15.10. UBI Pharma Inc
- LIST NOT EXHAUSTIVE
- 16. Appendix
- 16.1. About Us and Services
- 16.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook